嘉應制藥(002198.SZ):股東中聯集信忽悠式增持遭廣東證監局警示
格隆匯8月7日丨嘉應制藥(002198.SZ)公佈,公司股東中聯集信於2020年8月7日收到廣東證監局下發的《關於對中聯集信投資管理有限公司採取出具警示函措施的決定》([2020]117號)。
2018年7月25日,中聯集信通過嘉應制藥發佈股份增持公告,披露基於對嘉應制藥未來發展前景的信心以及內在價值的認可,計劃自2018年7月25日起12個月內增持合計不低於嘉應制藥總股本5%的股份。2019年7月15日,經嘉應制藥股東大會審議通過,中聯集信將增持計劃實施期限延長12個月。2020年7月27日,嘉應制藥公告稱,截至2020年7月24日,中聯集信僅增持了80.56萬股嘉應制藥股票,佔嘉應制藥總股本的0.16%。
中聯集信未如期完成增持嘉應制藥股票計劃,也未及時、充分披露不能按承諾實施增持計劃的風險信息,違反了《上市公司信息披露管理辦法》第二條和《上市公司監管指引第4號——上市公司實際控制人、股東、關聯方、收購人以及上市公司承諾及履行》第五條的規定。廣東證監局決定對中聯集信採取出具警示函的行政監管措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.